Various hydrocarbons have been released into the environment as a result of industrialization. An effective way of removing these materials without further environmental contamination is microbial bioremediation. Mycobacterium gilvum PYR-GCK, a bacteria isolated from a PAH polluted estuary, was studied using comparative shotgun proteomics to gain insight on its molecular activity while using pyrene and glucose as sole carbon and energy sources. Based on annotated genomic information, a confirmation analysis was first performed to confirm its pyrene degradation activity, using gas chromatography-mass spectrometry technology. One dimensional gel electrophoresis and liquid chromatography-mass spectrometry technologies employed in the proteomics analysis revealed the expression of pyrene degrading gene products along with upregulated expression of proteins functioning in the glyoxylate and shikimate pathways, in the pyrene-induced cells. The study also revealed the pathway of pyrene degraded intermediates, via partial gluconeogenesis, into the pentose phosphate pathway to produce precursors for nucleotides and amino acids biosynthesis.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10532-013-9622-9DOI Listing

Publication Analysis

Top Keywords

mycobacterium gilvum
8
gilvum pyr-gck
8
pyrene glucose
8
glyoxylate shikimate
8
chromatography-mass spectrometry
8
pyrene
5
global proteome
4
proteome study
4
study mycobacterium
4
pyr-gck grown
4

Similar Publications

Genetic variations underlying aminoglycoside resistance in antibiotic-induced Mycobacterium intracellulare mutants.

Infect Genet Evol

January 2025

Department of Microbiology, College of Medicine, Gyeongsang National University, Jinju, Republic of Korea; Department of Convergence of Medical Science, Gyeongsang National University, Jinju, Republic of Korea. Electronic address:

Mycobacterium avium complex (MAC) is an emerging pathogen leading to public health concerns in developing and developed countries, particularly among immunocompromised individuals and patients with structural lung diseases. Current clinical guidelines recommend combination antibiotic therapy for treating MAC pulmonary disease (MAC-PD). However, the rising prevalence of antibiotic resistance poses significant challenges, including treatment failure and clinical recurrence.

View Article and Find Full Text PDF

Recurrent NTM pulmonary disease despite avoidance of hot spring exposure in a plaque psoriasis patient treated with Secukinumab: a case report.

BMC Infect Dis

January 2025

National Clinical Research Center of Respiratory Diseases, Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, 100029, China.

Background: Recurrent Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD) related to treatment with Secukinumab has not been previously documented.

Case Presentation: Despite adherence to treatment and avoiding hot springs, a plaque psoriasis patient experienced persistent NTM-PD relapses.

Conclusions: There is potential association between Secukinumab, an IL-17A inhibitor, and NTM disease, echoing anti-TNF biologics' NTM risk, indicating the urgent need for further research on pathogenic mechanisms and risk factors.

View Article and Find Full Text PDF

Background: Non-tuberculous mycobacterial lung disease may coexist or precede lung cancer, yet a causal link remains unproven. This study aimed to elucidate the causal association between non-tuberculous mycobacteria (NTM) and lung cancer.

Methods: Summary data from genome-wide association studies (GWAS) for NTM, atypical mycobacterial lung infections, and various types of lung cancer were utilized.

View Article and Find Full Text PDF

(Mab), a nontuberculous mycobacterium, is increasing in prevalence worldwide and causes treatment-refractory pulmonary diseases. However, how Mab rewires macrophage energy metabolism to facilitate its survival is poorly understood. We compared the metabolic profiles of murine bone marrow-derived macrophages (BMDMs) infected with smooth (S)- and rough (R)-type Mab using extracellular flux technology.

View Article and Find Full Text PDF

New Frontiers in Fighting Mycobacterial Infections: Venom-Derived Peptides.

Probiotics Antimicrob Proteins

January 2025

Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran.

Notwithstanding the indefatigable endeavors to develop effective anti-mycobacterial therapies, mycobacterial infections still present a tough problem for medicine today. The problem is further complicated by the disquieting surge of drug-resistant mycobacterial pathogens, which considerably narrows the existing therapeutic options. Thus, there is a genuine need to discover novel anti-mycobacterial drugs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!